Trial Profile

Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orteronel (Primary) ; Bicalutamide; Buserelin; Buserelin; Flutamide; Goserelin; Goserelin; Leuprorelin; Leuprorelin; Triptorelin; Triptorelin
Indications Prostate cancer
Focus Therapeutic Use

13 Mar 2019 Planned End Date changed from 1 Jun 2024 to 1 Jun 2029.
13 Mar 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2025.
11 May 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Jun 2020, as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com